References
- Marcus EA, Scott DR. Gastric colonization by H. pylori. Helicobacter pylori. Singapore: Springer; 2016. p. 23–34.
- Konturek S, Konturek P, Konturek J, et al. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation. J Physiol Pharmacol. 2006;57:29.
- Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–490.
- Marshall B, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet. 1984;323(8390):1311–1315.
- Malfertheiner P, F M, O’morain C, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2016:66(1):6-30. gutjnl-2016-312288.
- Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut 2017. gutjnl-2017-314744.
- Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy: the III Working Group Consensus Report 2015. Dig Liver Dis. 2015;47(11):903–912.
- Malfertheiner P, Megraud F, O’morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–664.
- Roosendaal R, Kuipers EJ, Buitenwerf J, et al. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol. 1997;92:1480–1482.
- Daugule I, Karklina D, Rudzite D, et al. Prevalence of Helicobacter pylori infection among preschool children in Latvia: no significant decrease in prevalence during a ten year period. Scand J Public Health. 2016 Jun;44(4):418–422.
- Kalach N, Bontems P, Raymond J. Helicobacter pylori infection in children. Helicobacter. 2017;22(Suppl):1)e12414.
- Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367.
- Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439–443.
- Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111(7):949.
- Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Alimentary Pharmacol Therapeutics. 2015;42(6):685–695.
- Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6(6):e94.
- Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006;2:699–709.
- Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–1153.
- Muhsen K, Pasetti MF, Reymann MK, et al. Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive US adults with attenuated Salmonella typhi oral vaccine CVD 908-htrA. J Infect Dis. 2013;209(9):1452–1458.
- Velin D, Michetti P. Advances in vaccination against Helicobacter pylori. Expert Rev Gastroenterol Hepatol. 2010;4(2):157–166.
- Nilsson C, Skoglund A, Moran AP, et al. Lipopolysaccharide diversity evolving in Helicobacter pylori communities through genetic modifications in fucosyltransferases. PLoS One. 2008;3(11):e3811.
- Garhart CA, Redline RW, Nedrud JG, et al. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect Immun. 2002;70(7):3529–3538.
- Sun H, Yuan H, Tan R, et al. Immunodominant antigens that induce Th1 and Th17 responses protect mice against Helicobacter pylori infection. Oncotarget. 2018;9(15):12050.
- Gong Y, Tao L, Wang F, et al. Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine. Mol Med Rep. 2015;12(3):4123–4132.
- Guo L, Yin R, Xu G, et al. Immunologic properties and therapeutic efficacy of a multivalent epitope‐based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils. Helicobacter. 2017;22(6):e12428.
- Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2018. doi.org/10.1016/j.vaccine.2018.01.001